LFVN · XBRL financial data

Lifevantage financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LFVN's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue from contracts with customers	220,181	206,360	213,398	200,164	228,530	182,586
Cost of goods and services sold	38,187	38,097	43,387	41,440	44,864	40,973
Gross profit	181,994	168,263	170,011	158,724	183,666	141,613
Research and development	700	700	600	700	1,400	1,000
Selling, general and administrative	60,838	63,425	71,065	68,472	69,207	58,419
Total operating expenses	164,379	160,688	165,752	154,392	171,467	135,513
Operating income (loss)	17,615	7,575	4,259	4,332	12,199	6,100
Interest expense	17	10	(198)	(430)	—	—
Other income (expense)	(366)	(669)	(458)	(412)	(387)	(198)
Income tax expense (benefit)	4,338	1,571	1,459	1,413	2,438	994
Net income (loss)	12,894	3,120	2,540	2,937	9,805	5,072
Earnings per share, basic USD per share	0.92	0.24	0.20	0.24	0.80	0.40
Earnings per share, diluted USD per share	0.90	0.24	0.20	0.23	0.75	0.40
Weighted average shares, basic thousands of shares	14,070	12,886	12,557	12,458	12,251	12,534
Weighted average shares, diluted thousands of shares	14,268	13,069	12,567	12,986	12,987	12,702

Fiscal years (LFVN's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	23,174	20,190	21,605	16,886	20,201	14,920
Accounts receivable	2,925	3,338	1,612	2,949	3,294	2,990
Inventory	16,145	16,472	16,073	15,055	20,669	16,167
Prepaid and other current assets	4,772	5,205	4,753	2,443	6,095	2,834
Total current assets	48,054	46,957	44,284	37,646	50,894	38,297
Property and equipment, net	11,123	9,500	9,086	7,813	6,207	7,310
Right-of-use asset	13,700	11,040	8,738	9,569	8,041	6,715
Goodwill	—	—	—	—	0	465
Total assets	78,732	70,706	66,123	60,299	71,958	62,111
Accounts payable	6,744	7,462	3,505	5,853	4,600	5,156
Accrued liabilities	7,336	7,927	7,932	7,874	13,513	7,412
Total current liabilities	25,199	25,728	19,609	22,309	27,217	20,227
Lease liability, non-current	16,032	13,154	11,566	11,801	9,811	7,933
Total liabilities	41,925	39,190	31,474	34,308	37,317	28,522
Accumulated deficit	(92,346)	(98,437)	(98,305)	(108,738)	(104,147)	(103,462)
Total stockholders' equity	36,807	31,516	34,649	25,991	34,641	33,589
Total liabilities and equity	78,732	70,706	66,123	60,299	71,958	62,111
Common shares outstanding (cover page) thousands of shares	13,647	12,553	12,702	12,479	12,691	12,527

Fiscal years (LFVN's year ends in late June)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2022Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	12,894	3,120	2,540	2,937	9,805	5,072
Stock-based compensation	2,036	1,768	3,188	3,280	5,702	2,346
Depreciation and amortization	3,460	3,261	3,579	3,581	3,156	2,773
Net cash from operating activities	16,273	7,959	6,828	12,197	11,878	10,241
Purchases of property and equipment	3,741	1,530	3,067	2,245	1,371	3,571
Net cash from investing activities	(3,734)	(1,530)	(3,059)	(2,245)	(1,367)	(7,314)
Proceeds from issuing equity	1,379	133	0	—	—	—
Share repurchases	11,933	8,833	822	6,430	3,147	2,043
Dividends paid	0	378	1,586	6,940	2,067	2,344
Repayments of long-term debt	0	0	—	—	—	—
Net cash from financing activities	(11,453)	(8,952)	(2,357)	(14,417)	(7,598)	(7,783)
Net change in cash	1,036	(2,984)	1,415	(4,719)	3,315	(5,281)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lifevantage	14,920	42,377*	4,767*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Veru	23,880	not reported	(5,467)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85,234	0	(14,529)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Medicinova	25,416	458	(1,920)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
PDS Biotechnology	5,596	not reported	(2,793)*	56.0M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Sutro Biopharma	54,335	9,839	(38,290)*	16.6M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23,370	not reported	(29,626)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
iBio	56,395	0*	(6,228)*	64.3M	14.1 quarters	Q4 FY26 10-KJun 30, 2026
Seres Therapeutics	15,594	736	(22,394)*	9.9M	0.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.